Literature DB >> 16886198

Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation.

Joshua D Rabinowitz1, Peter M Lloyd, Patrik Munzar, Daniel J Myers, Steve Cross, Ramesh Damani, Reynaldo Quintana, Daniel A Spyker, Pravin Soni, James V Cassella.   

Abstract

A deficiency of most current drug products for treatment of acute conditions is slow onset of action. A promising means of accelerating drug action is through rapid systemic drug administration via deep lung inhalation. The speed of pulmonary drug absorption depends on the site of aerosol deposition within the lung and the dissolution rate and drug content of the deposited particles. Alveolar delivery of fast-dissolving, pure drug particles should in theory enable very rapid absorption. We have previously shown that heating of thin drug films generates vapor-phase drug that subsequently cools and condenses into pure drug particles of optimal size for alveolar delivery. Here we present a hand held, disposable, breath-actuated device incorporating this thermal aerosol technology, and its application to the delivery of alprazolam, an anti-panic agent, and prochlorperazine, an anti-emetic with recently discovered anti-migraine properties. Thermal aerosol particles of these drugs exist in an amorphous state, which results in remarkably rapid drug absorption from the lung into the systemic circulation, with peak left ventricular concentrations achieved within 20 s, even quicker than following rapid (5 s) intravenous infusion. Absorption of the thermal aerosol is nearly complete, with >80% absolute bioavailability found in both dogs and human normal volunteers. Copyright 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886198     DOI: 10.1002/jps.20694

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  The effect of film thickness on thermal aerosol generation.

Authors:  Dan J Myers; Ryan D Timmons; Amy T Lu; Ron L Hale; Dennis W Solas; Pravin Soni; Josh D Rabinowitz
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

Review 2.  Devices for dry powder drug delivery to the lung.

Authors:  Kai Berkenfeld; Alf Lamprecht; Jason T McConville
Journal:  AAPS PharmSciTech       Date:  2015-05-12       Impact factor: 3.246

Review 3.  Alternative delivery systems for agents to treat acute agitation: progress to date.

Authors:  Kimberly Nordstrom; Michael H Allen
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.

Authors:  Nicholas Gross; Leon S Greos; Eli O Meltzer; Selwyn Spangenthal; Robert S Fishman; Daniel A Spyker; James V Cassella
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

5.  Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.

Authors:  Chad J Reissig; Joseph A Harrison; Lawrence P Carter; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2014-09-09       Impact factor: 4.530

6.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.

Authors:  Daniel A Spyker; Robert A Riesenberg; James V Cassella
Journal:  J Clin Pharmacol       Date:  2015-05-06       Impact factor: 3.126

Review 7.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29

8.  The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.

Authors:  Tine Rikke Jørgensen; Charlotte Emborg; Karianne Dahlen; Mette Bøgelund; Andreas Carlborg
Journal:  BMC Psychiatry       Date:  2016-07-16       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.